Phosphoinositide 3-kinase in Health and Disease

Volume 2
Herausgegeben:Rommel, Christian; Vanhaesebroeck, Bart; Vogt, Peter K.

• Broschiertes Buch

Produktbeschreibung

PI3K has become a very intense area of research, with over 2000 publications on PI3K in PubMed for 2009 alone. The expectations for a therapeutic impact of intervention with PI3K activity are high, and progress in the clinical arena is being monitored by many. However, targeted therapies almost invariably encounter roadblocks, often exposing unresolved questions in the basic understanding of the target From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here the authors give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here

Produktdetails

• Current Topics in Microbiology and Immunology 347
• Verlag: Springer / Springer Berlin Heidelberg / Springer, Berlin
• Artikelnr. des Verlages: 978-3-642-26530-3
• Repr. d. Ausg. v. 2011
• Seitenzahl: 316
• Erscheinungstermin: 3. Dezember 2012
• Englisch
• Abmessung: 235mm x 155mm x 18mm
• Gewicht: 482g
• ISBN-13: 9783642265303
• ISBN-10: 3642265308
• Artikelnr.: 36769793

Inhaltsangabe

PI3K
From the bench to the clinic and back.
Oncogenetic mutations of PIK3CA in human cancers.
Structural effects of oncogenic PI3Kalpha mutations.
Comparing the roles of the p110 and p110 isoforms of PI3K in signaling and cancer.
Phophatidylinositol 3
kinase (PI3K): the oncoprotein.
AKT Signaling in Physiology and Disease.
Faithfull modeling of PTEN loss driven diseases in the mouse.
PI3K as a target for therapy in haematological malignancies.
Clinical Development of Phosphatidylinositol
3 Kinase Pathway Inhibitors.
From the bench to the bed side: PI3K pathway inhibitors in clinical development.
New Inhibitors of the PI3K
Akt
mTOR Pathway: Insights into mTOR Signaling From a New Generation of Tor Kinase Domain Inhibitors (TORKinibs).
Small molecule inhibitors of the PI3
kinase family.
Targeting the RTK
PI3K
mTOR axis in malignant glioma: overcoming resistance.
Subject index Contents of sister volume 1: PI3K Book Introduction.
PDK1: The major transducer of PI 3
kinase actions.
Protein Kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway.
Regulatory subunity of class IA PI3K.
The Regulation of Class IA PI 3
kinases by Inter
Subunit Interactions.
Phosphoinositide signalling pathways in metabolic regulation.
Role of RAS in the regulation of PI 3
kinase.
More than just kinases: the scaffolding function of PI3K.
PI3K signalling in neutrophils.
PI 3
kinase p110 Regulation of Platelet Integrin IIb3.
PI3Ks in lymphocyte signaling and development.
the neurodevelopmental implication of PI3K signaling.
PI3kinase regulation of skeletal muscle hypertrophy and atrophy.
Taking PI3Kdelta and PI3Kgamma one step ahead
Dual active PI3Kdelta/gamma inhibotrs for the treatment of immune
mediated inflammatory diseases.
Subject index